Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated December 4, 2023, serves as a report of a foreign private issuer. The document does not contain financial results for a specific reporting period but instead announces provisional dividend dates for the fiscal year 2024.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is exclusively focused on the administrative schedule for dividend payments.
Material Changes
No material changes to financial performance or operations are reported in this filing. The content is limited to the announcement of future dividend timelines.
Guidance, Outlook, and Management Commentary
Management has announced the following provisional dates for 2024 dividends. The filing explicitly states that these dates are indicative and may be subject to change.
- Q1 2024: Results announcement on May 1, 2024; Ordinary Shares ex-dividend on May 16, 2024; Payable on July 11, 2024.
- Q2 2024: Results announcement on July 31, 2024; Ordinary Shares ex-dividend on August 15, 2024; Payable on October 10, 2024.
- Q3 2024: Results announcement on October 30, 2024; Ordinary Shares ex-dividend on November 14, 2024; Payable on January 9, 2025.
- Q4 2024: Results announcement on February 5, 2025; Ordinary Shares ex-dividend on February 20, 2025; Payable on April 10, 2025.
American Depositary Shares (ADS) ex-dividend dates are listed as one day after the Ordinary Shares ex-dividend dates for each quarter.
Investor Verification Checklist
- Verify that the provisional dividend dates have not changed prior to the ex-dividend dates.
- Confirm the final dividend amounts per share, as this filing only provides dates, not values.
- Check for any subsequent filings regarding the Q1 2024 results announcement scheduled for May 1, 2024.